Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arvinas Holding Company ( (ARVN) ) has shared an announcement.
On May 11, 2026, Arvinas and its subsidiaries, together with Pfizer, entered a license agreement granting Rigel Pharmaceuticals exclusive global rights to develop, manufacture and commercialize VEPPANU, an FDA-approved oral PROTAC estrogen receptor degrader for ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer. Rigel will lead the U.S. launch and hold worldwide rights with sublicensing flexibility, while Arvinas and Pfizer retain a share of sublicensing revenues and continue ongoing development activities with Rigel contributing up to $40 million.
Under the deal, Arvinas and Pfizer will receive a $70 million upfront payment and $15 million tied to transition activities, plus eligibility for up to $320 million in future milestones and mid-teens to mid-20s tiered royalties on global VEPPANU sales, with all payments split evenly between the partners. The transaction, announced in a May 12, 2026 press release and subject to customary regulatory approvals, replaces certain unearned financial obligations under the prior Pfizer collaboration, potentially strengthening Arvinas’ cash position while shifting commercialization to Rigel, which aims to expand access to VEPPANU in a market where NCCN recently added the drug as a Category 2A treatment option for ESR1‑mutated HR+/HER2‑ advanced breast cancer.
The most recent analyst rating on (ARVN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
The score is held back primarily by weak financial performance (continued losses, significant cash burn, and 2025 revenue/gross profit volatility) and bearish technicals (below major moving averages with negative MACD). Offsetting factors include constructive catalyst-driven guidance and notable positive corporate events, led by FDA approval of VEPPANU and encouraging ARV-102 data.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas, Inc. is a New Haven, Conn.-based biotechnology company focused on targeted protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimera) platform to remove disease-causing proteins. The company, which co-developed VEPPANU with Pfizer as the first FDA-approved PROTAC, is advancing multiple investigational drugs for neurodegenerative disorders and various cancers, including programs targeting LRRK2, KRAS G12D, BCL6 and polyQ-AR.
Through its pipeline, Arvinas aims to address debilitating and life-threatening diseases, particularly in oncology and neurology, while leveraging partnerships such as its collaboration with Pfizer to bring novel protein degrader medicines to market.
Average Trading Volume: 883,462
Technical Sentiment Signal: Strong Sell
Current Market Cap: $646.6M
See more data about ARVN stock on TipRanks’ Stock Analysis page.